27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. - XML Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
: 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. - XML Representation

Active as of 2024-05-16
Raw xml | Download


<Citation xmlns="http://hl7.org/fhir">
  <id value="179613"/>
  <meta>
    <versionId value="1"/>
    <lastUpdated value="2023-11-26T18:47:26.987Z"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Citation</b><a name="179613"> </a><a name="hc179613"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourceCitation &quot;179613&quot; Version &quot;1&quot; Updated &quot;2023-11-26 18:47:26+0000&quot; </p></div><p><b>url</b>: <code>https://fevir.net/resources/Citation/179613</code></p><p><b>identifier</b>: FEvIR Object Identifier/179613, <code>https://pubmed.ncbi.nlm.nih.gov</code>/27308831</p><p><b>version</b>: 1.0.0-ballot</p><p><b>title</b>: 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.</p><p><b>status</b>: active</p><p><b>date</b>: 2024-05-16 12:17:54+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href="http://www.hl7.org/Special/committees/dss">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td>FEvIR Platform Use (Details: Citation Classification Type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use')</td><td>Medline Base <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#medline-base)</span></td></tr></table><p><b>jurisdiction</b>: World <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (m49.htm#001)</span></p><p><b>copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>approvalDate</b>: 2017-07-26</p><p><b>lastReviewDate</b>: 2022-03-17</p><p><b>author</b>: Computable Publishing®: MEDLINE-to-FEvIR Converter: </p><blockquote><p><b>classification</b></p><p><b>type</b>: Citation Source <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-classification-type.html">Citation Classification Type</a>#citation-source)</span></p><p><b>classifier</b>: MEDLINE <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: MEDLINE Citation Owner <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-classification-type.html">Citation Classification Type</a>#medline-owner)</span></p><p><b>classifier</b>: National Library of Medicine, Index Section <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (elements_descriptions.html#owner_value#NLM)</span></p></blockquote><p><b>currentState</b>: Medline Citation Status of Medline <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#medline-medline)</span>, PubMed PublicationStatus of epublish <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-publication-status-epublish)</span></p><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Received <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-received)</span></p><p><b>period</b>: ?? --&gt; 2016-04-01</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Accepted <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-accepted)</span></p><p><b>period</b>: ?? --&gt; 2016-06-02</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Entrez <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-entrez)</span></p><p><b>period</b>: ?? --&gt; 2016-06-17 06:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Pubmed <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-pubmed)</span></p><p><b>period</b>: ?? --&gt; 2016-06-17 06:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Medline <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-medline)</span></p><p><b>period</b>: ?? --&gt; 2017-07-27 06:00:00+0000</p></blockquote><blockquote><p><b>citedArtifact</b></p><p><b>identifier</b>: <code>https://pubmed.ncbi.nlm.nih.gov</code>/27308831, <code>https://www.ncbi.nlm.nih.gov/pmc/</code>/PMC4911003, <code>https://doi.org</code>/10.1371/journal.pone.0157660, pii/PONE-D-16-10077</p><h3>Titles</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Language</b></td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td>Primary title <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-title-type.html">Title Type</a>#primary)</span></td><td>English <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.5.0/CodeSystem-v3-ietf3066.html">Tags for the Identification of Languages</a>#en)</span></td><td>Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.</td></tr></table><h3>Abstracts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td>**OBJECTIVE:** Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in older men in the United States (USA) and Western Europe. Androgen-deprivation therapy alone (ADT) remains the first line of treatment in most cases, for metastatic disease. We performed a systematic review and meta-analysis of all randomized controlled trials (RCT) that compared the efficacy and adverse events profile of a chemohormonal therapy (ADT ± docetaxel) for metastatic hormone-naive prostate cancer (mHNPC).
**METHODS:** Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoint was overall survival. Data extracted from the studies were combined by using the hazard ratio (HR) or risk ratio (RR) with their corresponding 95% confidence intervals (95% CI).
**RESULTS:** The final analysis included 3 trials comprising 2,264 patients (mHNPC). Patients who received the chemohormonal therapy had a longer clinical progression-free survival interval (HR = 0.64; 95% CI: 0.55 to 0.75; p&amp;lt;0.00001), and no heterogeneity (Chi2 = 0.64; df = 1 [p = 0.42]; I2 = 0%). The biochemical progression-free survival (bPFS) also was higher in patients treated with ADT plus docetaxel (HR = 0.63; 95% CI: 0.57 to 0.69; p&amp;lt;0.00001), also with no heterogeneity noted (Chi2 = 0.48; df = 2 [p = 0.79]; I2 = 0%). Finally, the combination of ADT with docetaxel showed a superior overall survival (OS) compared with ADT alone (HR = 0.73; 95% CI: 0.64 to 0.84; p&amp;lt;0.0001), with moderate heterogeneity (Chi2 = 3.84; df = 2 [p = 0.15]; I2 = 48%). A random-effects model analysis was performed, and the results remained favorable to the use of ADT plus docetaxel (HR = 0.73; 95% CI: 0.60 to 0.89; p = 0.002). In the final combined analysis of the high-volume disease patients, the use of the combination therapy also favored an increased overall survival (HR = 0.67; 95% CI: 0.54 to 0.83; p = 0.0003). Regarding adverse events and severe toxicity (grade ≥3), the group receiving the combined therapy had higher rates of neutropenia, febrile neutropenia and fatigue.
**CONCLUSION:** The combination of ADT with docetaxel improved the clinical progression-free survival, bPFS and OS of patients with mHNPC. A superior OS was seen especially for patients with metastatic and high-volume disease. This contemporary combination therapy may now be offered as a first-line treatment for selected patients.</td></tr></table><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: http://clinicaltrials.gov/ct2/show/NCT00514540.</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011;60(2):279–90. Epub 2011/05/20. doi: S0302-2838(11)00477-5 [pii] 10.1016/j.eururo.2011.04.038 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/21592649/">https://pubmed.ncbi.nlm.nih.gov/21592649/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/21592649</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, et al. Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis. International braz j urol: official journal of the Brazilian Society of Urology. 2012;38(6):717–27. Epub 2013/01/11. .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/23302410/">https://pubmed.ncbi.nlm.nih.gov/23302410/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/23302410</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25(12):1596–605. Epub 2007/04/04. doi: JCO.2006.10.1949 [pii] 10.1200/JCO.2006.10.1949 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/17404365/">https://pubmed.ncbi.nlm.nih.gov/17404365/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/17404365</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. European urology. 2014;65(2):467–79. Epub 2013/12/11. 10.1016/j.eururo.2013.11.002 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/24321502/">https://pubmed.ncbi.nlm.nih.gov/24321502/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/24321502</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v69–77. Epub 2015/07/25. 10.1093/annonc/mdv222 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/26205393/">https://pubmed.ncbi.nlm.nih.gov/26205393/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/26205393</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Noguchi M, Noda S, Yoshida M, Ueda S, Shiraishi T, Itoh K. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol. 2004;11(2):103–9. Epub 2004/01/07. .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/14706014/">https://pubmed.ncbi.nlm.nih.gov/14706014/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/14706014</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England journal of medicine. 2004;351(15):1513–20. Epub 2004/10/08. 10.1056/NEJMoa041318 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/15470214/">https://pubmed.ncbi.nlm.nih.gov/15470214/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/15470214</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England journal of medicine. 2004;351(15):1502–12. Epub 2004/10/08. 10.1056/NEJMoa040720 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/15470213/">https://pubmed.ncbi.nlm.nih.gov/15470213/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/15470213</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Fizazi K, Jenkins C, Tannock IF. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol. 2015;26(8):1660–7. Epub 2015/05/24. 10.1093/annonc/mdv245</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/26002607/">https://pubmed.ncbi.nlm.nih.gov/26002607/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/26002607</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2013;14(2):149–58. Epub 2013/01/12. 10.1016/s1470-2045(12)70560-0 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/23306100/">https://pubmed.ncbi.nlm.nih.gov/23306100/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/23306100</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy plus docetaxel versus ADT alone for hormone-naive metastatic prostate cancer: Long-term analysis of the GETUG-AFU 15 phase III trial. 2015 Genitourinary Cancers Symposium Abstract 140 Presented February 26, 2015.</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F, et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. European urology. 2015. Epub 2015/11/28. 10.1016/j.eururo.2015.11.005 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/26610858/">https://pubmed.ncbi.nlm.nih.gov/26610858/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/26610858</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015;373(8):737–46. Epub 2015/08/06. 10.1056/NEJMoa1503747</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/26244877/">https://pubmed.ncbi.nlm.nih.gov/26244877/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/26244877</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 32:5s, 2014. (suppl; abstr LBA2).</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309(6964):1286–91. Epub 1994/11/12. .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/7718048/">https://pubmed.ncbi.nlm.nih.gov/7718048/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/7718048</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Clarke M, Oxman AD, (Editors). Cochrane Reviewers Handbook 4.1.1 [updated December 2000] In: The Cochrane Library, Issue 4, 2000. Oxford, Update Software.2000.</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Castro AA, Clark OA, Atallah AN. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. Sao Paulo Med J. 1999;117(3):138–9. Epub 1999/10/08. doi: S1516-3180(99)11700311 [pii]. .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/10511734/">https://pubmed.ncbi.nlm.nih.gov/10511734/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/10511734</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Egger M, Smith GD, Altman D. Systematic Reviews in Health Care. London: BMJ Books; 2001.</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34. Epub 1999/01/28. [pii]. .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/9921604/">https://pubmed.ncbi.nlm.nih.gov/9921604/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/9921604</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. Epub 2003/09/06. 10.1136/bmj.327.7414.557 327/7414/557 [pii].</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/12958120/">https://pubmed.ncbi.nlm.nih.gov/12958120/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/12958120</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig. 2010;30(4):229–41. Epub 2010/03/17. doi: 2 [pii] 10.2165/11532260-000000000-00000 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/20225906/">https://pubmed.ncbi.nlm.nih.gov/20225906/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/20225906</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Deeks JJ, Higgins JP, Altman DG. Analysing and presenting results In: Higgins JP, G S editor. Cochrane Handbook for Systematic Reviews of In- terventions (ed 426 [updated September 2006]). Chichester, United Kingdom: John Wiley &amp; Sons Ltd; 2006.</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. Epub 1986/09/01. doi: 0197-2456(86)90046-2 [pii]. .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/3802833/">https://pubmed.ncbi.nlm.nih.gov/3802833/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/3802833</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. Epub 1997/10/06.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/9310563/">https://pubmed.ncbi.nlm.nih.gov/9310563/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/9310563</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126(9):712–20. Epub 1997/05/01. .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/9139558/">https://pubmed.ncbi.nlm.nih.gov/9139558/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/9139558</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses—sometimes informative, usually misleading. BMJ. 1999;318(7197):1548–51. Epub 1999/06/04.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/10356018/">https://pubmed.ncbi.nlm.nih.gov/10356018/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/10356018</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol. 2002;2:3 Epub 2002/02/28.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/11860606/">https://pubmed.ncbi.nlm.nih.gov/11860606/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/11860606</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–94. Epub 2009/07/23. doi: 0000605-200908180-00136 [pii].</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/19622512/">https://pubmed.ncbi.nlm.nih.gov/19622512/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/19622512</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. The Lancet Oncology. 2015;16(7):787–94. Epub 2015/06/02. 10.1016/s1470-2045(15)00011-x .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/26028518/">https://pubmed.ncbi.nlm.nih.gov/26028518/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/26028518</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, et al. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology. 2013;81(3):611–6. Epub 2013/03/05. 10.1016/j.urology.2012.12.025 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/23452809/">https://pubmed.ncbi.nlm.nih.gov/23452809/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/23452809</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Thalgott M, Horn T, Heck MM, Maurer T, Eiber M, Retz M, et al. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. Journal of hematology &amp; oncology. 2014;7:20 Epub 2014/03/07. 10.1186/1756-8722-7-20</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/24598155/">https://pubmed.ncbi.nlm.nih.gov/24598155/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/24598155</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. European urology. 2012;62(2):213–9. Epub 2012/04/17. 10.1016/j.eururo.2012.03.053 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/22502942/">https://pubmed.ncbi.nlm.nih.gov/22502942/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/22502942</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet (London, England). 2011;378(9809):2104–11. Epub 2011/11/08. 10.1016/s0140-6736(11)61095-7</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/22056152/">https://pubmed.ncbi.nlm.nih.gov/22056152/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/22056152</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (London, England). 2009;373(9660):301–8. Epub 2008/12/19. 10.1016/s0140-6736(08)61815-2 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/19091394/">https://pubmed.ncbi.nlm.nih.gov/19091394/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/19091394</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Amato R, Stepankiw M, Gonzales P. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. Cancer chemotherapy and pharmacology. 2013;71(6):1629–34. Epub 2013/04/23. 10.1007/s00280-013-2163-4 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/23604530/">https://pubmed.ncbi.nlm.nih.gov/23604530/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/23604530</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Rajan P, Frew JA, Wilson JM, Azzabi AS, McMenemin RM, Stockley J, et al. Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer. Urol Oncol. 2015;33(8):337.e1–6. Epub 2015/06/21. 10.1016/j.urolonc.2015.05.012 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/26092557/">https://pubmed.ncbi.nlm.nih.gov/26092557/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/26092557</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the &quot;Docetaxel Era&quot;: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European urology. 2015;67(6):1028–38. Epub 2014/10/11. 10.1016/j.eururo.2014.09.032 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/25301760/">https://pubmed.ncbi.nlm.nih.gov/25301760/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/25301760</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: James ND, Sydes MR, Mason M, et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 33, 2015. (suppl; abstr 5001).</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Patrick-Miller LJ, Chen YH, Carducci MA, Cella D, DiPaola RS, Gartrell BA, et al. Quality of life (QOL) analysis from E3805, chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PrCa). J Clin Oncol 34, 2016. (suppl 2S; abstr 286).</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Morgan SC, Waldron TS, Eapen L, Mayhew LA, Winquist E, Lukka H. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis. Radiother Oncol. 2008;88(1):1–9. Epub 2008/05/27. doi: S0167-8140(08)00233-8 [pii] 10.1016/j.radonc.2008.04.013 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/18501455/">https://pubmed.ncbi.nlm.nih.gov/18501455/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/18501455</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26(8):1589–604. Epub 2015/06/05. 10.1093/annonc/mdv257</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/26041764/">https://pubmed.ncbi.nlm.nih.gov/26041764/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/26041764</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. The Lancet Oncology. 2013;14(2):117–24. Epub 2013/01/09. 10.1016/s1470-2045(12)70537-5 .</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/23294853/">https://pubmed.ncbi.nlm.nih.gov/23294853/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/23294853</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Kellokumpu-Lehtinen PL, Harmenberg U, Hervonen P, Joensuu TK, McDermott RS, Ginman C, et al. Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis. J Clin Oncol 32, 2014. (suppl 4; abstr 23).</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate Cancer (Version 1.2016). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Liaw BC, Oh WK. Is Docetaxel Chemotherapy a New Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer? The American Journal of Hematology/oncology 2015; 11(9):17–20</p></blockquote><blockquote><p><b>publicationForm</b></p><h3>PublishedIns</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Identifier</b></td><td><b>Title</b></td><td><b>PublisherLocation</b></td></tr><tr><td style="display: none">*</td><td>Periodical <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-published-in-type.html">Published In Type</a>#D020492)</span></td><td>Electronic ISSN Type/1932-6203, ISOAbbreviation/PLoS One, ISSN Linking/1932-6203, Medline Title Abbreviation/PLoS One, NLM Unique ID/101285081</td><td>PloS one</td><td>United States</td></tr></table><p><b>citedMedium</b>: Internet <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-medium.html">Cited Medium</a>#internet)</span></p><p><b>volume</b>: 11</p><p><b>issue</b>: 6</p><p><b>articleDate</b>: 2016</p><p><b>publicationDateText</b>: 2016</p><p><b>language</b>: English <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.5.0/CodeSystem-v3-ietf3066.html">Tags for the Identification of Languages</a>#en)</span></p><p><b>pageString</b>: e0157660</p></blockquote><blockquote><p><b>publicationForm</b></p><p><b>citedMedium</b>: Internet without issue <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-medium.html">Cited Medium</a>#internet-without-issue)</span></p><p><b>articleDate</b>: 2016-06-16</p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: Abstract <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-artifact-url-classifier.html">Artifact Url Classifier</a>#abstract)</span></p><p><b>url</b>: <a href="https://pubmed.ncbi.nlm.nih.gov/27308831/">https://pubmed.ncbi.nlm.nih.gov/27308831/</a></p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: DOI Based <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-artifact-url-classifier.html">Artifact Url Classifier</a>#doi-based)</span></p><p><b>url</b>: <a href="https://doi.org/10.1371/journal.pone.0157660">https://doi.org/10.1371/journal.pone.0157660</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Publishing Model <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#publishing-model)</span></p><p><b>classifier</b>: Electronic-eCollection <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#Electronic-eCollection)</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Chemical <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#chemical)</span></p><p><b>classifier</b>: Androgen Antagonists <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000726)</span>, Antineoplastic Agents <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000970)</span>, Taxoids <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D043823)</span>, Tubulin Modulators <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D050257)</span>, Docetaxel <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (chemical-substances#15H5577CQD; #D000077143)</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: MeSH Heading <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading)</span></p><p><b>artifactAssessment</b>: <a name="hcmeshHeading0"> </a></p><blockquote><p/><p><a name="meshHeading0"> </a></p><p><a name="hcmeshHeading0"> </a></p><p><b>artifact</b>: <a href="#">#</a></p><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Aged <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000368)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Androgen Antagonists <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000726)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Antineoplastic Agents <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000970)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Antineoplastic Combined Chemotherapy Protocols <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000971)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Docetaxel <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000077143)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Humans <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D006801)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Lymphatic Metastasis <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D008207)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Male <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D008297)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Middle Aged <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D008875)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Patient Safety <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D061214)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Prostatic Neoplasms <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D011471)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: drug therapy <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000188)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: mortality <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000401)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: pathology <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000473)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Randomized Controlled Trials as Topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016032)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Survival Analysis <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016019)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Taxoids <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D043823)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Treatment Outcome <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016896)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Tubulin Modulators <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D050257)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote></blockquote></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Publication Type <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#publication-type)</span></p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016428)</span>, Meta-Analysis <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D017418)</span>, Review <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016454)</span>, Systematic Review <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000078182)</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Knowledge Artifact Type <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#knowledge-artifact-type)</span></p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>artifactAssessment</b>: <span>: Classifier added by Computable Publishing LLC</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Citation Subset <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#citation-subset)</span></p><p><b>classifier</b>: IM <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (elements_descriptions.html#citationsubset#IM)</span></p></blockquote><blockquote><p><b>contributorship</b></p><p><b>complete</b>: true</p><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor0"> </a></p><blockquote><p/><p><a name="author0"> </a></p><p><a name="hcauthor0"> </a></p><p><b>name</b>: Tobias Engel Ayer Botrel </p></blockquote><p><b>forenameInitials</b>: TE</p><p><b>affiliation</b>: </p><ul><li><span>: Evidencias - A Kantar Health Company, Campinas, São Paulo, Brazil.</span></li><li><span>: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.</span></li></ul></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor1"> </a></p><blockquote><p/><p><a name="author1"> </a></p><p><a name="hcauthor1"> </a></p><p><b>name</b>: Otávio Clark </p></blockquote><p><b>forenameInitials</b>: O</p><p><b>affiliation</b>: </p><ul><li><span>: Evidencias - A Kantar Health Company, Campinas, São Paulo, Brazil.</span></li><li><span>: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.</span></li></ul></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor2"> </a></p><blockquote><p/><p><a name="author2"> </a></p><p><a name="hcauthor2"> </a></p><p><b>name</b>: Antônio Carlos Lima Pompeo </p></blockquote><p><b>forenameInitials</b>: AC</p><p><b>affiliation</b>: <span>: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.</span></p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor3"> </a></p><blockquote><p/><p><a name="author3"> </a></p><p><a name="hcauthor3"> </a></p><p><b>name</b>: Francisco Flávio Horta Bretas </p></blockquote><p><b>forenameInitials</b>: FF</p><p><b>affiliation</b>: <span>: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.</span></p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor4"> </a></p><blockquote><p/><p><a name="author4"> </a></p><p><a name="hcauthor4"> </a></p><p><b>name</b>: Marcus Vinicius Sadi </p></blockquote><p><b>forenameInitials</b>: MV</p><p><b>affiliation</b>: <span>: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.</span></p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor5"> </a></p><blockquote><p/><p><a name="author5"> </a></p><p><a name="hcauthor5"> </a></p><p><b>name</b>: Ubirajara Ferreira </p></blockquote><p><b>forenameInitials</b>: U</p><p><b>affiliation</b>: <span>: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.</span></p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor6"> </a></p><blockquote><p/><p><a name="author6"> </a></p><p><a name="hcauthor6"> </a></p><p><b>name</b>: Rodolfo Borges Dos Reis </p></blockquote><p><b>forenameInitials</b>: R</p><p><b>affiliation</b>: <span>: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.</span></p></blockquote></blockquote></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author0</b><a name="author0"> </a><a name="hcauthor0"> </a></p><p><b>name</b>: Tobias Engel Ayer Botrel </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author1</b><a name="author1"> </a><a name="hcauthor1"> </a></p><p><b>name</b>: Otávio Clark </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author2</b><a name="author2"> </a><a name="hcauthor2"> </a></p><p><b>name</b>: Antônio Carlos Lima Pompeo </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author3</b><a name="author3"> </a><a name="hcauthor3"> </a></p><p><b>name</b>: Francisco Flávio Horta Bretas </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author4</b><a name="author4"> </a><a name="hcauthor4"> </a></p><p><b>name</b>: Marcus Vinicius Sadi </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author5</b><a name="author5"> </a><a name="hcauthor5"> </a></p><p><b>name</b>: Ubirajara Ferreira </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author6</b><a name="author6"> </a><a name="hcauthor6"> </a></p><p><b>name</b>: Rodolfo Borges Dos Reis </p></blockquote><hr/><blockquote><p><b>Generated Narrative: ArtifactAssessment #meshHeading0</b><a name="meshHeading0"> </a><a name="hcmeshHeading0"> </a></p><p><b>artifact</b>: <a href="#">#</a></p><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Aged <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000368)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Androgen Antagonists <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000726)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Antineoplastic Agents <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000970)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Antineoplastic Combined Chemotherapy Protocols <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000971)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Docetaxel <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000077143)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Humans <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D006801)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Lymphatic Metastasis <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D008207)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Male <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D008297)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Middle Aged <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D008875)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Patient Safety <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D061214)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Prostatic Neoplasms <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D011471)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: drug therapy <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000188)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: mortality <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000401)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: pathology <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000473)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Randomized Controlled Trials as Topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016032)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Survival Analysis <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016019)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Taxoids <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D043823)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Treatment Outcome <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016896)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Tubulin Modulators <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D050257)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote></blockquote></div>
  </text>
  <contained>
    <Practitioner>
      <id value="author0"/>
      <name>
        <family value="Botrel"/>
        <given value="Tobias Engel Ayer"/>
      </name>
    </Practitioner>
  </contained>
  <contained>
    <Practitioner>
      <id value="author1"/>
      <name>
        <family value="Clark"/>
        <given value="Otávio"/>
      </name>
    </Practitioner>
  </contained>
  <contained>
    <Practitioner>
      <id value="author2"/>
      <name>
        <family value="Lima Pompeo"/>
        <given value="Antônio Carlos"/>
      </name>
    </Practitioner>
  </contained>
  <contained>
    <Practitioner>
      <id value="author3"/>
      <name>
        <family value="Horta Bretas"/>
        <given value="Francisco Flávio"/>
      </name>
    </Practitioner>
  </contained>
  <contained>
    <Practitioner>
      <id value="author4"/>
      <name>
        <family value="Sadi"/>
        <given value="Marcus Vinicius"/>
      </name>
    </Practitioner>
  </contained>
  <contained>
    <Practitioner>
      <id value="author5"/>
      <name>
        <family value="Ferreira"/>
        <given value="Ubirajara"/>
      </name>
    </Practitioner>
  </contained>
  <contained>
    <Practitioner>
      <id value="author6"/>
      <name>
        <family value="Borges Dos Reis"/>
        <given value="Rodolfo"/>
      </name>
    </Practitioner>
  </contained>
  <contained>
    <ArtifactAssessment>
      <id value="meshHeading0"/>
      <artifactReference>
        <reference value="#"/>
        <type value="Citation"/>
      </artifactReference>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D000368"/>
            <display value="Aged"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D000726"/>
            <display value="Androgen Antagonists"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <coding>
              <system value="https://meshb.nlm.nih.gov/"/>
              <code value="Q000627"/>
              <display value="therapeutic use"/>
            </coding>
          </classifier>
          <component>
            <type>
              <text value="is Major topic"/>
            </type>
            <classifier>
              <coding>
                <system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
                <code value="C49488"/>
                <display value="Yes"/>
              </coding>
            </classifier>
          </component>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D000970"/>
            <display value="Antineoplastic Agents"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <coding>
              <system value="https://meshb.nlm.nih.gov/"/>
              <code value="Q000627"/>
              <display value="therapeutic use"/>
            </coding>
          </classifier>
          <component>
            <type>
              <text value="is Major topic"/>
            </type>
            <classifier>
              <coding>
                <system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
                <code value="C49488"/>
                <display value="Yes"/>
              </coding>
            </classifier>
          </component>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D000971"/>
            <display value="Antineoplastic Combined Chemotherapy Protocols"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <coding>
              <system value="https://meshb.nlm.nih.gov/"/>
              <code value="Q000627"/>
              <display value="therapeutic use"/>
            </coding>
          </classifier>
          <component>
            <type>
              <text value="is Major topic"/>
            </type>
            <classifier>
              <coding>
                <system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
                <code value="C49488"/>
                <display value="Yes"/>
              </coding>
            </classifier>
          </component>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D000077143"/>
            <display value="Docetaxel"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D006801"/>
            <display value="Humans"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D008207"/>
            <display value="Lymphatic Metastasis"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D008297"/>
            <display value="Male"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D008875"/>
            <display value="Middle Aged"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D061214"/>
            <display value="Patient Safety"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D011471"/>
            <display value="Prostatic Neoplasms"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <coding>
              <system value="https://meshb.nlm.nih.gov/"/>
              <code value="Q000188"/>
              <display value="drug therapy"/>
            </coding>
          </classifier>
          <component>
            <type>
              <text value="is Major topic"/>
            </type>
            <classifier>
              <coding>
                <system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
                <code value="C49488"/>
                <display value="Yes"/>
              </coding>
            </classifier>
          </component>
        </component>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <coding>
              <system value="https://meshb.nlm.nih.gov/"/>
              <code value="Q000401"/>
              <display value="mortality"/>
            </coding>
          </classifier>
          <component>
            <type>
              <text value="is Major topic"/>
            </type>
            <classifier>
              <coding>
                <system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
                <code value="C49487"/>
                <display value="No"/>
              </coding>
            </classifier>
          </component>
        </component>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <coding>
              <system value="https://meshb.nlm.nih.gov/"/>
              <code value="Q000473"/>
              <display value="pathology"/>
            </coding>
          </classifier>
          <component>
            <type>
              <text value="is Major topic"/>
            </type>
            <classifier>
              <coding>
                <system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
                <code value="C49487"/>
                <display value="No"/>
              </coding>
            </classifier>
          </component>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D016032"/>
            <display value="Randomized Controlled Trials as Topic"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D016019"/>
            <display value="Survival Analysis"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D043823"/>
            <display value="Taxoids"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <coding>
              <system value="https://meshb.nlm.nih.gov/"/>
              <code value="Q000627"/>
              <display value="therapeutic use"/>
            </coding>
          </classifier>
          <component>
            <type>
              <text value="is Major topic"/>
            </type>
            <classifier>
              <coding>
                <system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
                <code value="C49488"/>
                <display value="Yes"/>
              </coding>
            </classifier>
          </component>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D016896"/>
            <display value="Treatment Outcome"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D050257"/>
            <display value="Tubulin Modulators"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <coding>
              <system value="https://meshb.nlm.nih.gov/"/>
              <code value="Q000627"/>
              <display value="therapeutic use"/>
            </coding>
          </classifier>
          <component>
            <type>
              <text value="is Major topic"/>
            </type>
            <classifier>
              <coding>
                <system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
                <code value="C49488"/>
                <display value="Yes"/>
              </coding>
            </classifier>
          </component>
        </component>
      </content>
    </ArtifactAssessment>
  </contained>
  <url value="https://fevir.net/resources/Citation/179613"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net"/>
    <value value="179613"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <system value="https://pubmed.ncbi.nlm.nih.gov"/>
    <value value="27308831"/>
  </identifier>
  <version value="1.0.0-ballot"/>
  <title
         value="27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis."/>
  <status value="active"/>
  <date value="2024-05-16T12:17:54+00:00"/>
  <publisher value="HL7 International / Clinical Decision Support"/>
  <contact>
    <name value="HL7 International / Clinical Decision Support"/>
    <telecom>
      <system value="url"/>
      <value value="http://www.hl7.org/Special/committees/dss"/>
    </telecom>
  </contact>
  <description
               value="This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
  <useContext>
    <code>
      <system value="http://hl7.org/fhir/citation-classification-type"/>
      <code value="fevir-platform-use"/>
      <display value="FEvIR Platform Use"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
        <code value="medline-base"/>
        <display value="Medline Base"/>
        <userSelected value="false"/>
      </coding>
    </valueCodeableConcept>
  </useContext>
  <jurisdiction>
    <coding>
      <system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
      <code value="001"/>
      <display value="World"/>
    </coding>
  </jurisdiction>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <approvalDate value="2017-07-26"/>
  <lastReviewDate value="2022-03-17"/>
  <author>
    <name value="Computable Publishing®: MEDLINE-to-FEvIR Converter"/>
  </author>
  <classification>
    <type>
      <coding>
        <system value="http://hl7.org/fhir/citation-classification-type"/>
        <code value="citation-source"/>
        <display value="Citation Source"/>
      </coding>
    </type>
    <classifier>
      <text value="MEDLINE"/>
    </classifier>
  </classification>
  <classification>
    <type>
      <coding>
        <system value="http://hl7.org/fhir/citation-classification-type"/>
        <code value="medline-owner"/>
        <display value="MEDLINE Citation Owner"/>
      </coding>
    </type>
    <classifier>
      <coding>
        <system
                value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value"/>
        <code value="NLM"/>
        <display value="National Library of Medicine, Index Section"/>
        <userSelected value="false"/>
      </coding>
    </classifier>
  </classification>
  <currentState>
    <coding>
      <system value="http://hl7.org/fhir/citation-status-type"/>
      <code value="medline-medline"/>
      <display value="Medline Citation Status of Medline"/>
    </coding>
  </currentState>
  <currentState>
    <coding>
      <system value="http://hl7.org/fhir/citation-status-type"/>
      <code value="pubmed-publication-status-epublish"/>
      <display value="PubMed PublicationStatus of epublish"/>
    </coding>
  </currentState>
  <statusDate>
    <activity>
      <coding>
        <system value="http://hl7.org/fhir/citation-status-type"/>
        <code value="pubmed-pubstatus-received"/>
        <display value="PubMed Pubstatus of Received"/>
      </coding>
    </activity>
    <period>
      <end value="2016-04-01"/>
    </period>
  </statusDate>
  <statusDate>
    <activity>
      <coding>
        <system value="http://hl7.org/fhir/citation-status-type"/>
        <code value="pubmed-pubstatus-accepted"/>
        <display value="PubMed Pubstatus of Accepted"/>
      </coding>
    </activity>
    <period>
      <end value="2016-06-02"/>
    </period>
  </statusDate>
  <statusDate>
    <activity>
      <coding>
        <system value="http://hl7.org/fhir/citation-status-type"/>
        <code value="pubmed-pubstatus-entrez"/>
        <display value="PubMed Pubstatus of Entrez"/>
      </coding>
    </activity>
    <period>
      <end value="2016-06-17T06:00:00.000Z"/>
    </period>
  </statusDate>
  <statusDate>
    <activity>
      <coding>
        <system value="http://hl7.org/fhir/citation-status-type"/>
        <code value="pubmed-pubstatus-pubmed"/>
        <display value="PubMed Pubstatus of Pubmed"/>
      </coding>
    </activity>
    <period>
      <end value="2016-06-17T06:00:00.000Z"/>
    </period>
  </statusDate>
  <statusDate>
    <activity>
      <coding>
        <system value="http://hl7.org/fhir/citation-status-type"/>
        <code value="pubmed-pubstatus-medline"/>
        <display value="PubMed Pubstatus of Medline"/>
      </coding>
    </activity>
    <period>
      <end value="2017-07-27T06:00:00.000Z"/>
    </period>
  </statusDate>
  <citedArtifact>
    <identifier>
      <system value="https://pubmed.ncbi.nlm.nih.gov"/>
      <value value="27308831"/>
    </identifier>
    <identifier>
      <system value="https://www.ncbi.nlm.nih.gov/pmc/"/>
      <value value="PMC4911003"/>
    </identifier>
    <identifier>
      <system value="https://doi.org"/>
      <value value="10.1371/journal.pone.0157660"/>
    </identifier>
    <identifier>
      <type>
        <coding>
          <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
          <code value="ACSN"/>
          <display value="Accession ID"/>
        </coding>
        <text value="pii"/>
      </type>
      <value value="PONE-D-16-10077"/>
    </identifier>
    <title>
      <type>
        <coding>
          <system value="http://hl7.org/fhir/title-type"/>
          <code value="primary"/>
          <display value="Primary title"/>
        </coding>
      </type>
      <language>
        <coding>
          <system value="urn:ietf:bcp:47"/>
          <code value="en"/>
          <display value="English"/>
        </coding>
      </language>
      <text
            value="Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis."/>
    </title>
    <abstract>
      <text
            value="**OBJECTIVE:** Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in older men in the United States (USA) and Western Europe. Androgen-deprivation therapy alone (ADT) remains the first line of treatment in most cases, for metastatic disease. We performed a systematic review and meta-analysis of all randomized controlled trials (RCT) that compared the efficacy and adverse events profile of a chemohormonal therapy (ADT ± docetaxel) for metastatic hormone-naive prostate cancer (mHNPC).
**METHODS:** Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoint was overall survival. Data extracted from the studies were combined by using the hazard ratio (HR) or risk ratio (RR) with their corresponding 95% confidence intervals (95% CI).
**RESULTS:** The final analysis included 3 trials comprising 2,264 patients (mHNPC). Patients who received the chemohormonal therapy had a longer clinical progression-free survival interval (HR = 0.64; 95% CI: 0.55 to 0.75; p&amp;lt;0.00001), and no heterogeneity (Chi2 = 0.64; df = 1 [p = 0.42]; I2 = 0%). The biochemical progression-free survival (bPFS) also was higher in patients treated with ADT plus docetaxel (HR = 0.63; 95% CI: 0.57 to 0.69; p&amp;lt;0.00001), also with no heterogeneity noted (Chi2 = 0.48; df = 2 [p = 0.79]; I2 = 0%). Finally, the combination of ADT with docetaxel showed a superior overall survival (OS) compared with ADT alone (HR = 0.73; 95% CI: 0.64 to 0.84; p&amp;lt;0.0001), with moderate heterogeneity (Chi2 = 3.84; df = 2 [p = 0.15]; I2 = 48%). A random-effects model analysis was performed, and the results remained favorable to the use of ADT plus docetaxel (HR = 0.73; 95% CI: 0.60 to 0.89; p = 0.002). In the final combined analysis of the high-volume disease patients, the use of the combination therapy also favored an increased overall survival (HR = 0.67; 95% CI: 0.54 to 0.83; p = 0.0003). Regarding adverse events and severe toxicity (grade ≥3), the group receiving the combined therapy had higher rates of neutropenia, febrile neutropenia and fatigue.
**CONCLUSION:** The combination of ADT with docetaxel improved the clinical progression-free survival, bPFS and OS of patients with mHNPC. A superior OS was seen especially for patients with metastatic and high-volume disease. This contemporary combination therapy may now be offered as a first-line treatment for selected patients."/>
    </abstract>
    <relatesTo>
      <type value="cites"/>
      <citation value="http://clinicaltrials.gov/ct2/show/NCT00514540."/>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011;60(2):279–90. Epub 2011/05/20. doi: S0302-2838(11)00477-5 [pii] 10.1016/j.eururo.2011.04.038 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/21592649/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="21592649"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, et al. Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis. International braz j urol: official journal of the Brazilian Society of Urology. 2012;38(6):717–27. Epub 2013/01/11. ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/23302410/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="23302410"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25(12):1596–605. Epub 2007/04/04. doi: JCO.2006.10.1949 [pii] 10.1200/JCO.2006.10.1949 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/17404365/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="17404365"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. European urology. 2014;65(2):467–79. Epub 2013/12/11. 10.1016/j.eururo.2013.11.002 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/24321502/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="24321502"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v69–77. Epub 2015/07/25. 10.1093/annonc/mdv222 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/26205393/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="26205393"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Noguchi M, Noda S, Yoshida M, Ueda S, Shiraishi T, Itoh K. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol. 2004;11(2):103–9. Epub 2004/01/07. ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/14706014/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="14706014"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England journal of medicine. 2004;351(15):1513–20. Epub 2004/10/08. 10.1056/NEJMoa041318 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/15470214/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="15470214"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England journal of medicine. 2004;351(15):1502–12. Epub 2004/10/08. 10.1056/NEJMoa040720 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/15470213/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="15470213"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Fizazi K, Jenkins C, Tannock IF. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol. 2015;26(8):1660–7. Epub 2015/05/24. 10.1093/annonc/mdv245"/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/26002607/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="26002607"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2013;14(2):149–58. Epub 2013/01/12. 10.1016/s1470-2045(12)70560-0 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/23306100/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="23306100"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <citation
                value="Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy plus docetaxel versus ADT alone for hormone-naive metastatic prostate cancer: Long-term analysis of the GETUG-AFU 15 phase III trial. 2015 Genitourinary Cancers Symposium Abstract 140 Presented February 26, 2015."/>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F, et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. European urology. 2015. Epub 2015/11/28. 10.1016/j.eururo.2015.11.005 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/26610858/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="26610858"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015;373(8):737–46. Epub 2015/08/06. 10.1056/NEJMoa1503747"/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/26244877/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="26244877"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <citation
                value="Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 32:5s, 2014. (suppl; abstr LBA2)."/>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309(6964):1286–91. Epub 1994/11/12. ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/7718048/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="7718048"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <citation
                value="Clarke M, Oxman AD, (Editors). Cochrane Reviewers Handbook 4.1.1 [updated December 2000] In: The Cochrane Library, Issue 4, 2000. Oxford, Update Software.2000."/>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Castro AA, Clark OA, Atallah AN. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. Sao Paulo Med J. 1999;117(3):138–9. Epub 1999/10/08. doi: S1516-3180(99)11700311 [pii]. ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/10511734/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="10511734"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <citation
                value="Egger M, Smith GD, Altman D. Systematic Reviews in Health Care. London: BMJ Books; 2001."/>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <citation
                value="Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011."/>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34. Epub 1999/01/28. [pii]. ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/9921604/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="9921604"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. Epub 2003/09/06. 10.1136/bmj.327.7414.557 327/7414/557 [pii]."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/12958120/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="12958120"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig. 2010;30(4):229–41. Epub 2010/03/17. doi: 2 [pii] 10.2165/11532260-000000000-00000 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/20225906/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="20225906"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <citation
                value="Deeks JJ, Higgins JP, Altman DG. Analysing and presenting results In: Higgins JP, G S editor. Cochrane Handbook for Systematic Reviews of In- terventions (ed 426 [updated September 2006]). Chichester, United Kingdom: John Wiley &amp; Sons Ltd; 2006."/>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. Epub 1986/09/01. doi: 0197-2456(86)90046-2 [pii]. ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/3802833/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="3802833"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. Epub 1997/10/06."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/9310563/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="9310563"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126(9):712–20. Epub 1997/05/01. ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/9139558/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="9139558"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses—sometimes informative, usually misleading. BMJ. 1999;318(7197):1548–51. Epub 1999/06/04."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/10356018/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="10356018"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol. 2002;2:3 Epub 2002/02/28."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/11860606/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="11860606"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–94. Epub 2009/07/23. doi: 0000605-200908180-00136 [pii]."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/19622512/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="19622512"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. The Lancet Oncology. 2015;16(7):787–94. Epub 2015/06/02. 10.1016/s1470-2045(15)00011-x ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/26028518/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="26028518"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, et al. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology. 2013;81(3):611–6. Epub 2013/03/05. 10.1016/j.urology.2012.12.025 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/23452809/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="23452809"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Thalgott M, Horn T, Heck MM, Maurer T, Eiber M, Retz M, et al. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. Journal of hematology &amp; oncology. 2014;7:20 Epub 2014/03/07. 10.1186/1756-8722-7-20"/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/24598155/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="24598155"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. European urology. 2012;62(2):213–9. Epub 2012/04/17. 10.1016/j.eururo.2012.03.053 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/22502942/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="22502942"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet (London, England). 2011;378(9809):2104–11. Epub 2011/11/08. 10.1016/s0140-6736(11)61095-7"/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/22056152/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="22056152"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (London, England). 2009;373(9660):301–8. Epub 2008/12/19. 10.1016/s0140-6736(08)61815-2 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/19091394/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="19091394"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Amato R, Stepankiw M, Gonzales P. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. Cancer chemotherapy and pharmacology. 2013;71(6):1629–34. Epub 2013/04/23. 10.1007/s00280-013-2163-4 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/23604530/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="23604530"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Rajan P, Frew JA, Wilson JM, Azzabi AS, McMenemin RM, Stockley J, et al. Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer. Urol Oncol. 2015;33(8):337.e1–6. Epub 2015/06/21. 10.1016/j.urolonc.2015.05.012 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/26092557/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="26092557"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the &quot;Docetaxel Era&quot;: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European urology. 2015;67(6):1028–38. Epub 2014/10/11. 10.1016/j.eururo.2014.09.032 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/25301760/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="25301760"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <citation
                value="James ND, Sydes MR, Mason M, et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 33, 2015. (suppl; abstr 5001)."/>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <citation
                value="Patrick-Miller LJ, Chen YH, Carducci MA, Cella D, DiPaola RS, Gartrell BA, et al. Quality of life (QOL) analysis from E3805, chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PrCa). J Clin Oncol 34, 2016. (suppl 2S; abstr 286)."/>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Morgan SC, Waldron TS, Eapen L, Mayhew LA, Winquist E, Lukka H. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis. Radiother Oncol. 2008;88(1):1–9. Epub 2008/05/27. doi: S0167-8140(08)00233-8 [pii] 10.1016/j.radonc.2008.04.013 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/18501455/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="18501455"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26(8):1589–604. Epub 2015/06/05. 10.1093/annonc/mdv257"/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/26041764/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="26041764"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. The Lancet Oncology. 2013;14(2):117–24. Epub 2013/01/09. 10.1016/s1470-2045(12)70537-5 ."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/23294853/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="23294853"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <citation
                value="Kellokumpu-Lehtinen PL, Harmenberg U, Hervonen P, Joensuu TK, McDermott RS, Ginman C, et al. Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis. J Clin Oncol 32, 2014. (suppl 4; abstr 23)."/>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <citation
                value="NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate Cancer (Version 1.2016). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf."/>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <citation
                value="Liaw BC, Oh WK. Is Docetaxel Chemotherapy a New Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer? The American Journal of Hematology/oncology 2015; 11(9):17–20"/>
    </relatesTo>
    <publicationForm>
      <publishedIn>
        <type>
          <coding>
            <system value="http://hl7.org/fhir/published-in-type"/>
            <code value="D020492"/>
            <display value="Periodical"/>
          </coding>
        </type>
        <identifier>
          <type>
            <coding>
              <system
                      value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn"/>
              <code value="Electronic"/>
              <display value="Electronic"/>
            </coding>
            <text value="Electronic ISSN Type"/>
          </type>
          <system value="https://portal.issn.org"/>
          <value value="1932-6203"/>
        </identifier>
        <identifier>
          <type>
            <coding>
              <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
              <code value="XX"/>
              <display value="Organization identifier"/>
            </coding>
            <text value="ISOAbbreviation"/>
          </type>
          <system
                  value="https://www.issn.org/services/online-services/access-to-the-ltwa/"/>
          <value value="PLoS One"/>
        </identifier>
        <identifier>
          <type>
            <coding>
              <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
              <code value="XX"/>
              <display value="Organization identifier"/>
            </coding>
            <text value="ISSN Linking"/>
          </type>
          <system
                  value="https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/"/>
          <value value="1932-6203"/>
        </identifier>
        <identifier>
          <type>
            <coding>
              <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
              <code value="XX"/>
              <display value="Organization identifier"/>
            </coding>
            <text value="Medline Title Abbreviation"/>
          </type>
          <system
                  value="https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html"/>
          <value value="PLoS One"/>
        </identifier>
        <identifier>
          <type>
            <coding>
              <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
              <code value="XX"/>
              <display value="Organization identifier"/>
            </coding>
            <text value="NLM Unique ID"/>
          </type>
          <system
                  value="https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local"/>
          <value value="101285081"/>
        </identifier>
        <title value="PloS one"/>
        <publisherLocation value="United States"/>
      </publishedIn>
      <citedMedium>
        <coding>
          <system value="http://hl7.org/fhir/cited-medium"/>
          <code value="internet"/>
          <display value="Internet"/>
        </coding>
      </citedMedium>
      <volume value="11"/>
      <issue value="6"/>
      <articleDate value="2016"/>
      <publicationDateText value="2016"/>
      <language>
        <coding>
          <system value="urn:ietf:bcp:47"/>
          <code value="en"/>
          <display value="English"/>
        </coding>
      </language>
      <pageString value="e0157660"/>
    </publicationForm>
    <publicationForm>
      <citedMedium>
        <coding>
          <system value="http://hl7.org/fhir/cited-medium"/>
          <code value="internet-without-issue"/>
          <display value="Internet without issue"/>
        </coding>
      </citedMedium>
      <articleDate value="2016-06-16"/>
    </publicationForm>
    <webLocation>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/artifact-url-classifier"/>
          <code value="abstract"/>
          <display value="Abstract"/>
        </coding>
      </classifier>
      <url value="https://pubmed.ncbi.nlm.nih.gov/27308831/"/>
    </webLocation>
    <webLocation>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/artifact-url-classifier"/>
          <code value="doi-based"/>
          <display value="DOI Based"/>
        </coding>
      </classifier>
      <url value="https://doi.org/10.1371/journal.pone.0157660"/>
    </webLocation>
    <classification>
      <type>
        <coding>
          <system
                  value="http://hl7.org/fhir/cited-artifact-classification-type"/>
          <code value="publishing-model"/>
          <display value="Publishing Model"/>
          <userSelected value="false"/>
        </coding>
      </type>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="Electronic-eCollection"/>
          <display value="Electronic-eCollection"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
    </classification>
    <classification>
      <type>
        <coding>
          <system
                  value="http://hl7.org/fhir/cited-artifact-classification-type"/>
          <code value="chemical"/>
          <display value="Chemical"/>
          <userSelected value="false"/>
        </coding>
      </type>
      <classifier>
        <coding>
          <system value="https://meshb.nlm.nih.gov/"/>
          <code value="D000726"/>
          <display value="Androgen Antagonists"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
      <classifier>
        <coding>
          <system value="https://meshb.nlm.nih.gov/"/>
          <code value="D000970"/>
          <display value="Antineoplastic Agents"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
      <classifier>
        <coding>
          <system value="https://meshb.nlm.nih.gov/"/>
          <code value="D043823"/>
          <display value="Taxoids"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
      <classifier>
        <coding>
          <system value="https://meshb.nlm.nih.gov/"/>
          <code value="D050257"/>
          <display value="Tubulin Modulators"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
      <classifier>
        <coding>
          <system
                  value="https://www.cas.org/support/documentation/chemical-substances"/>
          <code value="15H5577CQD"/>
          <userSelected value="false"/>
        </coding>
        <coding>
          <system value="https://meshb.nlm.nih.gov/"/>
          <code value="D000077143"/>
          <display value="Docetaxel"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
    </classification>
    <classification>
      <type>
        <coding>
          <system
                  value="http://hl7.org/fhir/cited-artifact-classification-type"/>
          <code value="mesh-heading"/>
          <display value="MeSH Heading"/>
        </coding>
      </type>
      <artifactAssessment>
        <reference value="#meshHeading0"/>
        <type value="ArtifactAssessment"/>
      </artifactAssessment>
    </classification>
    <classification>
      <type>
        <coding>
          <system
                  value="http://hl7.org/fhir/cited-artifact-classification-type"/>
          <code value="publication-type"/>
          <display value="Publication Type"/>
        </coding>
      </type>
      <classifier>
        <coding>
          <system value="https://meshb.nlm.nih.gov/"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
      <classifier>
        <coding>
          <system value="https://meshb.nlm.nih.gov/"/>
          <code value="D017418"/>
          <display value="Meta-Analysis"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
      <classifier>
        <coding>
          <system value="https://meshb.nlm.nih.gov/"/>
          <code value="D016454"/>
          <display value="Review"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
      <classifier>
        <coding>
          <system value="https://meshb.nlm.nih.gov/"/>
          <code value="D000078182"/>
          <display value="Systematic Review"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
    </classification>
    <classification>
      <type>
        <coding>
          <system
                  value="http://hl7.org/fhir/cited-artifact-classification-type"/>
          <code value="knowledge-artifact-type"/>
          <display value="Knowledge Artifact Type"/>
          <userSelected value="false"/>
        </coding>
      </type>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
      <artifactAssessment>
        <display value="Classifier added by Computable Publishing LLC"/>
      </artifactAssessment>
    </classification>
    <classification>
      <type>
        <coding>
          <system
                  value="http://hl7.org/fhir/cited-artifact-classification-type"/>
          <code value="citation-subset"/>
          <display value="Citation Subset"/>
          <userSelected value="false"/>
        </coding>
      </type>
      <classifier>
        <coding>
          <system
                  value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset"/>
          <code value="IM"/>
          <display value="IM"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
    </classification>
    <contributorship>
      <complete value="true"/>
      <entry>
        <contributor>
          <reference value="#author0"/>
          <type value="Practitioner"/>
          <display value="Botrel TE"/>
        </contributor>
        <forenameInitials value="TE"/>
        <affiliation>
          <display
                   value="Evidencias - A Kantar Health Company, Campinas, São Paulo, Brazil."/>
        </affiliation>
        <affiliation>
          <display
                   value="Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil."/>
        </affiliation>
      </entry>
      <entry>
        <contributor>
          <reference value="#author1"/>
          <type value="Practitioner"/>
          <display value="Clark O"/>
        </contributor>
        <forenameInitials value="O"/>
        <affiliation>
          <display
                   value="Evidencias - A Kantar Health Company, Campinas, São Paulo, Brazil."/>
        </affiliation>
        <affiliation>
          <display
                   value="Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil."/>
        </affiliation>
      </entry>
      <entry>
        <contributor>
          <reference value="#author2"/>
          <type value="Practitioner"/>
          <display value="Lima Pompeo AC"/>
        </contributor>
        <forenameInitials value="AC"/>
        <affiliation>
          <display
                   value="Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil."/>
        </affiliation>
      </entry>
      <entry>
        <contributor>
          <reference value="#author3"/>
          <type value="Practitioner"/>
          <display value="Horta Bretas FF"/>
        </contributor>
        <forenameInitials value="FF"/>
        <affiliation>
          <display
                   value="Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil."/>
        </affiliation>
      </entry>
      <entry>
        <contributor>
          <reference value="#author4"/>
          <type value="Practitioner"/>
          <display value="Sadi MV"/>
        </contributor>
        <forenameInitials value="MV"/>
        <affiliation>
          <display
                   value="Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil."/>
        </affiliation>
      </entry>
      <entry>
        <contributor>
          <reference value="#author5"/>
          <type value="Practitioner"/>
          <display value="Ferreira U"/>
        </contributor>
        <forenameInitials value="U"/>
        <affiliation>
          <display
                   value="Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil."/>
        </affiliation>
      </entry>
      <entry>
        <contributor>
          <reference value="#author6"/>
          <type value="Practitioner"/>
          <display value="Borges Dos Reis R"/>
        </contributor>
        <forenameInitials value="R"/>
        <affiliation>
          <display
                   value="Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil."/>
        </affiliation>
      </entry>
    </contributorship>
  </citedArtifact>
</Citation>